Caissa Capital Management ltd. 13D and 13G filings for Avalo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-06-29 08:22 am Sale | 2023-06-26 | 13G | Avalo Therapeutics, Inc. AVTX | Caissa Capital Management ltd. | 0 0.000% | -6,146 (Position Closed) | Filing |
| 2023-04-19 4:38 pm Purchase | 2023-04-18 | 13G | Avalo Therapeutics, Inc. AVTX | Caissa Capital Management ltd. | 6,146 11.190% | 339 (+5.84%) | Filing |
| 2023-02-14 4:09 pm Purchase | 2023-02-14 | 13G | Avalo Therapeutics, Inc. AVTX | Caissa Capital Management ltd. | 5,807 10.570% | 1,721 (+42.13%) | Filing |
| 2022-08-08 07:23 am Purchase | 2022-07-25 | 13G | Avalo Therapeutics, Inc. AVTX | Caissa Capital Management ltd. | 4,086 10.430% | 1,968 (+92.90%) | Filing |
| 2022-05-17 3:45 pm Purchase | 2022-05-04 | 13G | Avalo Therapeutics, Inc. AVTX | Caissa Capital Management ltd. | 2,118 5.410% | 2,118 (New Position) | Filing |